Drug Database
AN

anti-H5N1 avian influenza antibodies (Fabenflu / FBF001)

✓ Approved

Fab'entech · Polyclonal Antibodies · Polyclonal Antibodies

What is anti-H5N1 avian influenza antibodies?

anti-H5N1 avian influenza antibodies is a polyclonal antibodies developed by Fab'entech. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesFabenflu, FBF001
CompanyFab'entech
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Fab'entech

Therapeutic Indications

anti-H5N1 avian influenza antibodies is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsInfluenza✓ Approved

Related Research Articles

PubMedTransboundary and emerging diseases2026-08-30

A Multi-Reassortant H3N8 Avian Influenza Virus Derived From Migratory Birds in Eastern China Exhibits Cross-Species Transmission Potential.

Guo Yunfei Y, Yang Zhonglong Z, Yang Hui H, Miao Xinyu X et al.

Migratory birds are one of the main reservoirs and long-distance transmission vectors of avian influenza viruses (AIVs). A migratory-bird-origin H3N8 subtype AIV (A/wild bird/Huadong/sy17/2024, hereafter named as WD/HDsy17/24) was isolated and identified in Jiangsu Province, Eastern China, in 2024. However, few studies have been conducted on the cross-species transmission potential of H3N8 AIVs from migratory birds. Phylogenetic analysis indicated that the eight gene segments of WD/HDsy17/24 originated from different subtypes of AIV such as H3N8, H1, H5N1, H5N2, and H7N7 and was a multirecombinant virus. WD/HDsy17/24 virus showed a binding affinity to both SAα-2, 3-galactose (Gal) and SA α-2, 6 Gal receptors, relatively weak thermal stability and pH stability. The SPF chicken pathogenicity indicated that the virus only causes mild respiratory symptoms and leads to lung hemorrhage and congestion. The mice pathogenicity indicated that the body weight of infected mice drops to the lowest value on the third day after infection, the lung-to-body ratio significantly increases, and inflammatory or edema lesions appear in the lungs. Moreover, this virus can infect guinea pigs through contact transmission and aerosol transmission routes from infected SPF chickens. After infection, obvious secretions can be seen in the eyes of guinea pigs. In the contact transmission group, viral shedding was detected in the nasal wash of one guinea pig at 6 days postinfection (dpi). In the aerosol transmission group, viral shedding was detected in the nasal washes of one guinea pig at both 10 and 12 dpi and in another guinea pig at 14 dpi. After 21 days, the seroconversion rate of serum antibodies in both groups is 100%. These findings underscore the need for continued surveillance of H3N8 viruses to identify circulating strains that may potentially threaten human health.

PMID 42668438
Read full article →
PubMedJapanese journal of infectious diseases2026-08-30

A facile method for purifying viral immunogens using magnetic beads to generate neutralizing antibodies.

Kitayama Shota S, Kaida Atsushi A, Ikuta Kazuyoshi K, Shinagawa Hideo H et al.

Human parainfluenza virus type 3 (HPIV-3), an increasingly significant respiratory pathogen affecting both pediatric and elderly populations, currently lacks effective prophylactic or therapeutic interventions. The development of antibody-based therapeutics with the potential to prevent or treat HPIV-3 infection remains an active area of investigation. However, a major limitation of such antibody therapies is the emergence of escape mutant strains. Combination therapy employing multiple neutralizing antibodies targeting distinct epitopes has been explored as a strategy to circumvent viral escape in influenza and human immunodeficiency virus infections. However, the probability of obtaining multiple neutralizing antibodies, including those against HPIV-3, is generally low. Here, to maximize the presentation of viral surface epitopes to immune cells, we purified HPIV-3 virus using magnetic bead-based technology. The resulting antigen-magnetic bead complexes were immobilized and used to immunize mice. This strategy employs viable and infectious virion as immunogens, thereby enabling immune cells to recognize the native antigenic architecture of the viral surface with high fidelity. This method, which permits immunization while preserving the viral surface structure to the greatest extent and may be broadly applicable to many viruses, provide a simple and rapid approach for developing therapeutic antibodies during public health emergencies.

PMID 42669542
Read full article →
PubMed[Rinsho ketsueki] The Japanese journal of clinical hematology2026-08-30

[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].

Kawamoto Hiroshi H, Kawase Takakazu T, Nagano Seiji S

Cancer immunotherapy using patient-derived T cells genetically modified in vitro has been demonstrated to be effective. However, issues such as cost, time, and unstable quality must be resolved. To overcome these barriers, we developed the TCR-PS cell method, in which a specific TCR gene is introduced into pluripotent stem cells (PS cells), such as ES cells or iPS cells, and T cells are generated from those PS cells. We are currently preparing for a clinical trial in acute myeloid leukemia, targeting the WT1 antigen, with iPS cells provided by the CiRA Foundation as the starting material. In parallel, we are also investigating this approach for viral infections and preparing for clinical trials in COVID-19, with HLA-deficient ES cells as the starting material. This method should enable stockpiling of T cell therapies against known viruses such as SARS or avian influenza. Even for outbreaks caused by unknown viruses, it should be possible to produce T cell therapies within 100 days after the virus genome is defined.

PMID 42669514
Read full article →
PubMedCaspian journal of internal medicine2026-08-30

Viral respiratory infections and their co-occurrence among patients hospitalized in Ayatollah Rouhani Hospital, Babol, 2021-2024.

Firouzjahi Alireza A, Rouhi Samaneh S, Ranaee Mohammad M, Ahmadnia Zahra Z et al.

Vaccination has reduced the viral respiratory diseases in the community, but it has not ended. This study was conducted to determine the distribution of COVID-19, the influenza virus, and the human respiratory syncytial virus (RSV). This retrospective, descriptive-analytical study was conducted based on patient file information in Babol City (2021-2024). Clinical examination of the patient, computed tomography (CT), and real-time polymerase chain reaction (PCR) were used to identify the viruses in 10,567 patients. Mean, standard deviation (SD), distribution (%), and logistic regression were used to analyze the data using SPSS-23 (p<0.05). 83.34% and 16.65% of patients suffered from COVID-19 (12.95% ≥ 50 years old) and influenza (15.42%, ≤ 50 years old), respectively. The most underlying diseases were related to cardiovascular disease (17.47%). Female patients suspected of COVID-19 (females; 14.14% versus (vs) males; 11.87%) and influenza (females; 14.90% vs males; 15.62%) were more than male patients. COVID-19 (12.91%) and influenza (15.27%) in 2022 and 2023 showed a high distribution, respectively. Co-occurrence of COVID-19 and influenza was observed in one female. Gender, season, and year (each with a P-value of P=0.00) was associated in this descriptive analysis with the distribution of COVID-19. A significant relationship between season and year with the distribution of influenza was observed. A high distribution of COVID-19 was diagnosed among patients. Gender and year of study had a significant effect on COVID-19. Diagnosis and differentiation of the viral agent by molecular methods should be performed in a patient.

PMID 42668995
Read full article →
PubMedCureus2026-08-30

Acute EBV-Associated Systemic Inflammatory Syndrome Presenting as PUO With FDG-Avid Generalized Lymphadenopathy, Autoimmune Serological Positivity and Myopericarditis Mimicking Lymphoma and Connective Tissue Disease: A Diagnostic Challenge.

Abbasi Abdul Haleem AH, Job Mridhu M, Faiza Fahmida F, Rahman Ameena A et al.

Pyrexia of unknown origin (PUO) remains a diagnostic challenge, particularly when associated with lymphadenopathy, multisystem involvement and positive autoimmune serology. Distinguishing between infectious, inflammatory and malignant causes is often difficult, especially when advanced imaging demonstrates findings suggestive of lymphoma. A previously healthy man in his late 40s presented with a 10-day history of intermittent fever, myalgia, joint stiffness and pleuritic chest pain. During admission, he developed photophobia, mild neck stiffness, progressive upper and lower limb pain and weakness resulting in impaired mobility. Investigations demonstrated marked systemic inflammation with a C-reactive protein (CRP) of 235 mg/L and an erythrocyte sedimentation rate (ESR) of 105 mm/hr despite a normal white cell count (WCC). Extensive microbiological investigations including blood cultures, cerebrospinal fluid analysis, bacterial and fungal molecular testing, tuberculosis screening and viral polymerase chain reaction (PCR) testing were negative apart from detectable Epstein-Barr virus (EBV) DNA and positive EBV IgM serology. Autoimmune screening revealed positive ANA, anti-Ro52, anti-Ro60 and anti-La antibodies with low complement C4. Cardiac magnetic resonance imaging (MRI) confirmed acute myopericarditis. Positron emission tomography-computed tomography (PET-CT) demonstrated fluorodeoxyglucose (FDG)-avid supra- and infradiaphragmatic lymphadenopathy with splenic involvement highly suspicious for lymphoma. However, excisional cervical lymph node biopsy demonstrated reactive lymphoid hyperplasia without evidence of malignancy. Clinical improvement began approximately during the second week after admission and occurred without immunosuppressive therapy.

PMID 42669013
Read full article →
PubMedResearch and practice in thrombosis and haemostasis2026-08-30

Coagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis (CAGUYAMA study): a multicenter, open-label, nonrandomized clinical trial.

Takeyama Masahiro M, Ogiwara Kenichi K, Ozu Naoki N, Sasai Kana K et al.

Emicizumab prophylaxis reduces bleeding in people with hemophilia A. However, factor (F)VIII is still required to manage breakthrough bleeding and for surgical procedures. The optimal additional FVIII dose during such events remains unclear because of emicizumab's baseline hemostatic activity. To assess FVIII-induced changes in global coagulation potential in people with hemophilia A without inhibitors treated with emicizumab and to inform FVIII dosing during prophylaxis. The multicenter "Coagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis" study enrolled 100 people with hemophilia A (aged ≥4 years) receiving emicizumab at 13 centers in Japan. For eligible bleeding or surgical events, FVIII (standard or extended half-life) was administered at a target dose of 30 IU/kg (allowable range, 25-35 IU/kg). Paired blood samples were obtained pre- and post-FVIII administration. The primary endpoint was the change in clot waveform analysis-adjusted maximum coagulation rate, expressed as IMCR% relative to pooled normal plasma and untreated severe hemophilia A plasma. Secondary endpoints included peak thrombin in the thrombin generation assay, rotational thromboelastometry, clinical hemostasis, and safety. Anti-emicizumab antibodies were used in vitro to isolate the effects of FVIII. Thirty-two FVIII-treated events in 24 people with hemophilia A (15 bleeding events and 17 surgical events) were analyzed. The clot waveform analysis-adjusted maximum coagulation rate increased from 39.4% to 92.1% post-FVIII and from 3.2% to 78.6% under anti-emicizumab conditions. Peak thrombin in the thrombin generation assay increased from 249 to 348 nM (IMCR%: from 55.4% to 88.0%) and from 6.4% to 74.6% under anti-emicizumab conditions. All events achieved effective hemostasis. No thromboembolic events, thrombotic microangiopathy, or hypersensitivity reactions were reported. FVIII administered at a target dose of 30 IU/kg (allowable range, 25-35 IU/kg) improved global coagulation parameters and achieved effective hemostasis without thrombotic complications, warranting evaluation as part of emicizumab prophylaxis.

PMID 42668556
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-H5N1 avian influenza antibodies